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This study was conducted to reexamine the hypothe-
sis that human metapneumovirus (hMPV) will not infect
turkeys. Six groups of 2-week-old turkeys (20 per group)
were inoculated oculonasally with 1 of the following: nonin-
fected cell suspension; hMPV genotype A1, A2, B1, or B2;
or avian metapneumovirus (aMPV) subtype C. Poults inoc-
ulated with hMPV showed nasal discharge days 4–9 post-
exposure. Specific viral RNA and antigen were detected by
reverse-transcription PCR and immunohistochemical eval-
uation, respectively, in nasal turbinates of birds exposed to
hMPV. Nasal turbinates of hMPV-infected turkeys showed
inflammatory changes and mucus accumulation. Each of
the 4 hMPV genotypes caused a transient infection in
turkeys as evidenced by clinical signs, detection of hMPV
in turbinates, and histopathologic examination. Detailed
investigation of cross-species pathogenicity of hMPV and
aMPV and its importance for human and animal health is
needed.
H
uman metapneumovirus (hMPV) is a negative-sense,
single-stranded, nonsegmented RNA virus of the
genus Metapneumovirus of subfamily Pneumovirinae of
the family Paramyxoviridae, a large family of viruses that
affect humans and animals (1). Recently identified, hMPV
is noted for causing respiratory tract infections in children
(2). The virus was isolated from nasopharyngeal swabs
collected from 28 children over a period of 20 years in the
Netherlands, and it is thought to have been circulating in
human populations for at least 50 years (2). hMPV has 2
major genetic lineages (A and B) and at least 4 subgroups
identified so far, according to analysis of fusion, attach-
ment glycoprotein, and phosphoprotein genes (3). The
virus has worldwide distribution, and reports have identi-
fied hMPV from the United States, Canada, United
Kingdom, Italy, Germany, France, Israel, Australia, Asian
countries, and Peru (4,5).
The disease caused by hMPV ranges from mild upper
respiratory tract infection to severe bronchiolitis or bron-
chitis and pneumonia. It affects all age groups, but it is
more severe in young, elderly, and immunocompromised
persons (6). Serologic surveys indicate that the virus is
ubiquitous in nature and that new infections can occur
throughout life because of incomplete protection and
genetic heterogeneity of the virus (3,7,8). Clinically, the
disease is similar to that of human respiratory syncytial
virus and is second only to human respiratory syncytial
virus as 1 of the leading causes of bronchiolitis in young
children (9).
Recent studies have shown that avian metapneu-
movirus (aMPV) subtype C isolates from domestic turkeys
and wild birds in the United States show high sequence
homology to hMPV (10,11). Both viruses belong to genus
Metapneumovirus and share a projected amino acid identi-
ty of 56%–88% (11). An upper respiratory tract pathogen
of poultry, aMPV has global distribution (12). The United
States was considered free of aMPV until an outbreak of
respiratory tract infection occurred in turkey flocks in
Colorado in May 1996 (13). Later, in 1997, the disease
appeared in Minnesota, the largest turkey-producing state
in the country. Serologic evidence now exists for the
spread of aMPV into neighboring states of Iowa,
Wisconsin, South Dakota, and North Dakota (14). The
aMPV C identified in the United States has been reported
only in North America and is antigenically and genetically
different from subtypes A, B, and D detected in Europe,
Asia, Africa, and South America (15–18). 
Although hMPVand aMPVare closely related, they are
not reported to cause cross-infection. Aprevious attempt to
experimentally infect chickens and turkeys with hMPV
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hypothesis that hMPV will not infect turkeys by exposing
2-week-old turkeys to 4 genotypes of hMPV.
Materials and Methods
Cells and Virus
LLC-MK2 cells (ATCC no. CCL-7) were maintained in
Minimum Essential Medium (MEM) (Invitrogen, Grand
Island, New York, USA) supplemented with 3% bovine
fetal serum, 2 mmol/L L-glutamine, nonessential amino
acids, 100 IU/mL penicillin G sodium, and 100 µg/mL
streptomycin sulfate. Four genotypes of hMPV based on G
gene were provided by the University of Iowa for this
study: A1 (GenBank accession no. DQ312456), A2
(DQ312449), B1 (DQ312452), and B2 (DQ312457).
Genotype A1 was isolated from a nasal wash sample of a
3-year-old girl by propagation on LLC-MK2 cells for 29
days. Genotypes A2 and B1 were isolated from nasal wash
samples of 7- and 1-year-old girls, respectively, by propa-
gation on LLC-MK2 cells for 14 days. Genotype B2 was
isolated from a nasopharyngeal sample of a 19-year-old
woman by propagation on LLC-MK2 cells for 20 days.
After primary isolation, these viruses were further propa-
gated in LLC-MK2 cells in opti-MEM (Invitrogen) with 2
µg/mL trypsin (replenished every other day), 100 IU/mL
of penicillin G sodium, 100 µg/mL streptomycin, and no
serum.
aMPV C was isolated from the nasal turbinates of 8-
week-old turkeys with acute upper respiratory tract infec-
tion. The virus was passaged 6 times on chicken embryo
fibroblasts, then 6 times on Vero cells. The virus, designat-
ed as aMPV/Minnesota/Turkey/19/2003 (aMPV MN 19),
was used with a titer of 105 50% tissue culture infective
dose (TCID50)/mL.
Birds
A total of 120 2-week-old turkey poults (Large White,
Nicholas) from an aMPV-naive breeder flock that was not
vaccinated for aMPV were used (Institutional Biosafety
Committee [ID 785] and Institutional Animal Care and
Use Committee approved protocol #0505A69986,
University of Minnesota, Saint Paul, MN, USA). These
turkey poults were free of aMPV, Mycoplasma melea-
gridis, M. synoviae, M. gallisepticum, Bordetella avium,
and Newcastle disease virus.
Experimental Design
Turkey poults were divided into 6 groups of 20 each.
Poults in each group were inoculated oculonasally with
200 µL(50 µLeach in each eye and nostril) of 1 of the fol-
lowing: noninfected LLC-MK2 cell suspension (sham-
inoculated controls), 1 of the 4 genotypes of hMPV (A1,
A2, B1, B2), or aMPV C (positive controls). Poults in the
4 treatment groups received fresh, untitrated virus propa-
gated in LLC-MK2 cells. To ascertain the amount of virus
inoculated into poults in each group, each inoculum was
later titrated by serial dilutions in LLC-MK2 cells. Poults
were monitored daily for clinical signs. Two randomly
selected poults from each group were killed for necropsy
and sample collection at days 3, 5, and 7 postexposure.
Nasal turbinates, tracheas, and lungs were tested for viral
RNA by reverse-transcription (RT) PCR with specific
primers (consensus primers for all of the 4 genotypes) for
hMPVand aMPVas described below. Tissue sections were
stained with hematoxylin and eosin and examined for
histopathologic lesions and for viral antigen by immuno-
histochemical methods (19). Sera collected from poults in
each group at days 14 and 21 postexposure were tested
with aMPV-ELISA (20). No convincing evidence exists
for any cross-reactivity between hMPV and aMPV.
Clinical Sign Scoring
Turkey poults were monitored daily for any clinical
signs. A clinical sign scoring system was used to record
signs shown by those exposed to the viruses (21). Briefly,
poults in each group were given a score of 0 when they
showed no clinical signs; a score of 1 for unilateral nasal
discharge; 2 for bilateral nasal discharge; or 3 for thick,
copious, bilateral nasal discharge. Unilateral sinus
swelling was recorded as score 1, bilateral sinus swelling
as 2, unilateral conjunctivitis as 1, and bilateral conjunc-
tivitis as 2. The total score for each bird was expressed as
the sum of individual scores mentioned above.
RT-PCR
Nasal turbinates, tracheas, and lungs were collected in
MEM (Invitrogen) containing 100 IU/mL penicillin G
sodium and 100 µg/mL streptomycin to prepare a 20% tis-
sue homogenate. After centrifugation at 3,000 × g for 10
min to remove tissue debris, an additional centrifugation
was performed at 8,000 × g for 10 min, and the supernatant
was collected and used for RT-PCR. Viral RNA was
extracted from the tissue homogenate supernatant by using
a commercial viral RNA extraction kit (Qiagen, Valencia,
CA, USA). One-step RT-PCR was performed by using a
commercially available 1-step RT-PCR kit (Qiagen). Two
primers designed on the basis of the hMPV fusion protein
gene, 5′-GAGCAAATCCCAGACA-3′ and 5′-GAAA
ACTGCCGCACAACATTTAG-3′, were used as forward
and reverse primers, respectively (22). A 50-µL reaction
was set for each tissue sample with the following temper-
ature conditions: reverse transcription at 50°C for 30 min,
initial denaturation at 94°C for 10 min, 35 cycles of
annealing at 54°C for 1 min, extension at 72°C for 1 min,
and denaturation at 94°C for 30 sec, followed by a final
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then analyzed by electrophoresis on a 1.2% agarose gel. A
separate RT-PCR was set for each tissue sample by using
specific primers designed from the matrix protein gene of
aMPV to look for any cross-reactivity. The protocol
described by Shin et al. (23) was used. The forward primer
was 5′-ACAGTGTGTGAGTTAAAAG-3′ (M1) starting
from base 335, and the reverse primer was 5′- TGAC
TTCAGGACATATCTC-3′ (M2) starting from base 754 of
the US isolate of aMPV (aMPV/Minnesota/Turkey/
2a/1997).
Virus Isolation
Nasal turbinate homogenate from poults exposed to the
4 genotypes of hMPV was injected onto LLC-MK2 cells
for virus isolation. Five blind passages (14 days each) were
done, and the cells were examined for any cytopathic
effects. At the endpoint of each passage, 3 cycles of freeze-
thaw were done and the cell culture supernatant was tested
for hMPV RNA by RT-PCR as described above.
Histopathologic and Immunohistochemical
Evaluations
Nasal turbinates, tracheas, and lungs were fixed in 10%
buffered neutral formalin. Tissue sections were stained
with hematoxylin and eosin and examined for histopatho-
logic changes.
An immunoperoxidase procedure (19) originally devel-
oped to detect aMPV antigen was modified to detect
hMPV antigen in formalin-fixed nasal turbinate, trachea,
and lung tissues by using hMPV B2 polyclonal sera from
rabbits. The tissue sections were also tested by using
aMPV polyclonal sera from rabbits (19).
Serologic and Bacteriologic Examination
Serum samples were collected from turkey poults at
days 14 and 21 postexposure. Samples were examined for
antibodies by an aMPV-ELISA (20) that used aMPV sub-
type C whole-antigen–coated plates and anti-turkey IgG
conjugate as the secondary antibody.
To exclude the possibility of any bacterial infections,
nasal and tracheal swabs were streaked on blood agar and
McConkey agar plates. The plates were incubated at 37°C
for 3 days, after which they were examined for any bacte-
rial pathogens.
Results
Virus Titers 
The 4 genotypes of hMPV showed cytopathic effects in
LLC-MK2 cells 10–14 days postinoculation. Cytopathic
effects consisted mainly of cell rounding and formation of
syncytium. hMPV genotypes A1, A2, and B1 inocula had
a titer of 103 TCID50/mL each. Genotype B2 inoculum had
a titer of 105 TCID50/mL. The aMPV C inoculum had a
titer of 105 TCID50/mL.
Clinical Sign Scoring 
Poults inoculated with any of the 4 hMPV genotypes
had unilateral or bilateral nasal discharge (Table 1;
Figure 1), which varied from watery to thick mucus.
Clinical signs started on day 4 postexposure and stopped
on day 9 postexposure. Those infected with hMPVA1 had
a clinical score range of 1–2, and 6 of 20 showed clinical
signs. Poults infected with hMPV A2 had a score range of
1–8, and 12 of 20 showed clinical signs. Those inoculated
with hMPV B1 had a score range of 1–7, and 7 of 20
showed clinical signs. The group inoculated with hMPV
B2 had the most poults that showed clinical signs (14 of
20); score range was 2–8. Poults inoculated with aMPV
MN 19 showed severe clinical signs and had an average
score of 14.17 (Table 1). The main signs were thick,
mucous, bilateral nasal discharge and infraorbital sinus
swelling. 
RT-PCR
At day 3 postexposure, RT-PCR detected hMPV viral
RNAin the nasal turbinates of poults in each group exposed
to hMPV. Viral RNA was also detected at day 5 postexpo-
sure in 1 bird exposed to hMPV B2 (Table 2). Tracheas and
lungs did not show any viral RNA. Sham-inoculated birds
were negative for hMPV. The aMPV RNA was not detect-
ed in unexposed or hMPV-exposed poults. Those infected
with aMPV showed viral RNA in nasal turbinate (Table 2)
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specific RT-PCR on days 3, 5, and 7 postexposure.
Virus Isolation
No cytopathic effects were detected in LLC-MK2 cell
cultures inoculated with the nasal turbinate homogenate
from birds exposed to any one of the 4 genotypes of
hMPV. No hMPV RNA was detected from the cell culture
supernatant by RT-PCR after 5 blind passages.
Histopathologic and Immunohistochemical Evaluations
At days 3 and 5 postexposure, each of the 4 genotypes
had caused mild to moderate histopathologic lesions in the
nasal turbinates of poults inoculated with hMPV.
Inflammatory changes were more pronounced in those
inoculated with hMPV B2 than with any of the other 3
genotypes. Lesions consisted of infiltration of inflammato-
ry cells in the lamina propria, mainly lymphocytes,
macrophages, and plasma cells (Figure 2A). Mucus had
accumulated in the nasal cavity, and mucous glands had
dilated. Tracheas of poults inoculated with hMPV B2
showed mild inflammatory changes in the form of infiltra-
tion of inflammatory cells on day 5 postexposure (Figure
2B), whereas lungs did not show any histopathologic
lesions. Tissues from sham-inoculated poults also did not
show any lesions (Figures 2C and D). Nasal turbinates and
tracheas of poults infected with aMPV showed infiltration
of inflammatory cells (Figures 2E and F), dilation of
mucosal glands, and multifocal loss of cilia in turbinates
(Figure 2E).
On day 3 postexposure, immunohistochemical evalua-
tion showed hMPV antigen in the epithelial surface of
nasal turbinates of poults in each group inoculated with
hMPV (Figure 3A). No antigen was detected in tracheas or
lungs. On days 3, 5, and 7 postexposure, those infected
with aMPV showed viral antigen in turbinate (Figure 3B)
and trachea tissues (data not shown). Sham-inoculated
birds did not show antigen in tissues (Figure 3C).
Serologic and Bacteriologic Examination 
No antibodies were detected by aMPV-ELISA in sera
collected from poults exposed to hMPV at 14 and 21 days
postexposure. However, aMPV-infected poults had posi-
tive aMPV-ELISA results at 14 and 21 days postexposure
(data not shown). No cross-reactivity between aMPV and
hMPV was detected by either test conducted using aMPV
specific reagents, whereas their respective controls with
aMPV-infected samples showed positive reactions. No
pathogenic bacterial colonies were isolated from nasal or
tracheal swabs collected from any of the 120 poults.
Discussion
All 4 genotypes of hMPV did infect turkeys, as evi-
denced by clinical signs, RT-PCR results, immunohisto-
chemical findings, and histopathologic changes in the
nasal turbinates and tracheas of exposed turkeys. These
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Figure 1. Clinical signs of turkey poults exposed to human metap-
neumovirus B2, showing nasal discharge (solid arrows) and
swollen eyelids (dotted arrows).findings contradict those of van den Hoogen et al., who
detected neither clinical signs nor virus replication in juve-
nile turkeys inoculated with hMPV nor experimental
reproduction of infection in chickens (2).
In our study, 2-week-old turkeys in the four groups
were inoculated oculonasally with hMPV. Those receiving
either dose of hMPV (2×102 TCID50 or 2×104 TCID50)
developed clinical signs. In contrast, van den Hoogen et al.
inoculated 5×104 TCID50 of hMPV in the conjunctivae and
respiratory tracts of 4 juvenile turkeys (age and breed of
turkeys were not mentioned) and over a 3-week period
examined the birds for clinical signs and virus replication
by sampling cloacal and throat swabs. Although they inoc-
ulated more virus than we did, their birds did not show
clinical signs, so the amount of virus inoculated may not
be the reason for the different results. Possible reasons for
the contradictory results could be origin of the virus;
source, age, and immune status of the turkeys used; and the
samples that were analyzed. With aMPV infection,
younger turkeys show more severe clinical signs than older
turkeys (19,21); and nasal turbinate, a major predilection
site for aMPV replication in turkeys (21), is where we
detected hMPV.
In our study, severity of clinical signs and lesions var-
ied with different genotypes, possibly because of differ-
ences in titers inoculated, which can potentially influence
virus dissemination and pathogenicity. The virus inocula
were titrated in LLC-MK2 cells after inoculating birds.
The endpoint of titration was 14 days postinoculation of
the virus in cell cultures; to ensure fresh inocula, we decid-
ed to use untitrated virus. The main limitation of this
approach was that we could not use a uniform titer of each
virus inoculum. Therefore, we could not infer any informa-
tion about differences in severity of infection in turkeys
with respect to different genotypes of hMPV.
Clinical signs appeared in 30%–70% birds in the groups
exposed to the 4 genotypes of hMPV. The clinical signs
were similar to those of birds experimentally infected with
aMPV C (21). The main clinical sign observed in birds
infected with aMPV C is watery to thick mucous discharge
(21), and our poults exposed to hMPV showed watery to
thick mucous nasal discharge. The main difference in
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Figure 2. Histopathologic appearance of nasal turbinate and trachea tissue (magnification ×200). A) Nasal turbinates of turkey poults
exposed to human metapneumovirus (hMPV) B2, showing infiltration of inflammatory cells (hematoxylin and eosin staining; solid arrow).
B) Trachea of turkey poults exposed to hMPV B2, showing mild inflammation with infiltration of a few inflammatory cells in the lamina
propria (solid arrow). C) Nasal turbinate of sham-inoculated turkey poults. D) Trachea of sham-inoculated turkey poults. E) Nasal
turbinate of turkey poults exposed to avian metapneumovirus (aMPV C), showing infiltration of inflammatory cells and multifocal loss of
cilia (solid arrows). F) Trachea of turkey poults exposed to aMPV C, showing mild inflammation with infiltration of a few inflammatory cells
in the lamina propria (solid arrow). Dotted arrows indicate mucosal surface.clinical signs in our poults infected with hMPV was the
absence of infraorbital sinus swelling, which is often asso-
ciated with aMPV infection in turkeys (21).
Infiltration of inflammatory cells was observed in the
nasal turbinates of poults infected with hMPV and aMPV.
Nasal turbinates of poults infected with aMPV showed
multifocal loss of cilia, whereas this lesion was not
observed in those infected with hMPV. Immuno-
histochemical evaluation showed hMPV antigen in the
epithelial surface of nasal turbinates; however, the staining
was not as intense as we observed from aMPV infections
(Figure 3B). The lack of detection of hMPV antibodies in
the sera and antigens in tissues by serologic testing and
immunohistochemical evaluation using aMPV reagents,
respectively, indicates little to no cross-reactivity between
aMPV and hMPV. However, cross-reactivity between a
conserved region in aMPV nucleoprotein (N) with hMPV
has been reported (24). We think that whole aMPV virus
antigen or aMPV polyclonal serum-based detection sys-
tems may not work in the same way as affinity-purified
anti-N or monoclonal antibodies.
A synthetic aMPV N-peptide–based ELISA could
detect aMPV subtypes A, B, and C (25), whereas whole-
virus–based ELISAs with plates coated with European
subtypes of aMPV antigen could not detect aMPV C anti-
bodies and vice versa (25). Even with aMPV subtypes, the
whole-virus antigen-based detection systems did not show
cross-reaction between subtypes, whereas a conserved
region of nucleocapsid protein or synthetic peptide–based
detection systems showed cross-reactivity. This could also
occur with cross-reaction between hMPV and aMPV.
Possible zoonotic potential of metapneumoviruses and
their coexistence, if any, across species barriers must be
considered. Recent studies have shown that most infec-
tious agents, especially newly emerging pathogens, can be
transmitted between humans and animals (26). Taylor et al.
reviewed literature on 1,415 species of human pathogens
and identified 61% of them and 75% of emerging human
disease pathogens as zoonotic. In this context, our data
suggest hMPV and aMPV merit further investigations
regarding cross-species transmission (26).
Mice, cotton rats, hamsters, ferrets, and primate species
such as rhesus monkeys and African green monkeys have
been used to experimentally reproduce the disease caused
by hMPV (27,28). Hamsters, ferrets, and green monkeys
have been shown to replicate hMPV and produce neutral-
izing antibodies (27). Replication of the virus in infected
lung was also experimentally shown in mice and cotton
rats (28). Although hMPV replicated in the upper and
lower respiratory tract of hamsters and ferrets, these ani-
mals did not show any clinical signs (27). Hamelin et al.
reported that BALB/c mice infected with hMPV showed
ruffled hair, breathing difficulty, and weight loss (28). On
the other hand, our infected turkeys showed respiratory
signs in the form of watery to thick mucous nasal dis-
charge and eyelid swelling.
Histopathologic changes in the form of interstitial
inflammation and alveolitis have been observed in cotton
rats and mice infected with hMPV (28). In our turkey
poults, we did not detect inflammatory lesions in the lungs,
although nasal turbinates and tracheas showed infiltration
of inflammatory cells.
In our study, each of the 4 genotypes of hMPV caused
a transient infection in turkey poults, as evidenced by clin-
ical sign scores from days 4 to 9 postexposure, detection of
hMPV RNA in nasal turbinates at days 3 and 5 postexpo-
sure, and histopathologic lesions in the turbinates and tra-
cheas. Ours is the first report of an experimental infection
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Figure 3. Immunohistochemical findings for nasal turbinates, showing peroxidase staining of viral antigen in the epithelial surface (mag-
nification ×400; arrows). A) Turkey poults exposed to human metapneumovirus (hMPV B2).  B) Turkey poults exposed to avian meta-
pneumovirus (aMPV C). C) Sham-inoculated turkey poults.of turkeys with hMPV, and it opens up the possibility of
using turkeys as infection models for this virus. Our data
indicate a need for detailed investigation of the cross-
species pathogenicity of hMPV and aMPV and signifi-
cance of these viruses for human and animal health.
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